ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) updated its FY17 earnings guidance on Thursday. The company provided EPS guidance of $3.83-4.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.84. The company issued revenue guidance of $182.10 million, compared to the consensus revenue estimate of prior $3.58-3.94.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.79 by $0.19. The business had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. ANI Pharmaceuticals’s quarterly revenue was up 43.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.11 earnings per share.

A number of research analysts recently weighed in on the stock. Canaccord Genuity assumed coverage on shares of ANI Pharmaceuticals in a research report on Monday, July 31st. They set a buy rating and a $60.00 price objective on the stock. Zacks Investment Research raised shares of ANI Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, July 5th. Finally, BidaskClub raised shares of ANI Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, August 18th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of Hold and an average target price of $67.33.

COPYRIGHT VIOLATION NOTICE: “ANI Pharmaceuticals, Inc. (ANIP) Issues FY17 Earnings Guidance” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/11/02/ani-pharmaceuticals-inc-anip-issues-fy17-earnings-guidance.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.